Migraine Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Pulmatrix, Vaxxinity, Inc., Tonix Pharma

August 30 18:43 2023
Migraine Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies,  Mechanism of Action, Route of Administration by DelveInsight | Pulmatrix, Vaxxinity, Inc., Tonix Pharma
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Migraine pipeline constitutes 30+ key companies continuously working towards developing 30+ Migraine treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Migraine Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 


Migraine Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Migraine Market.


Some of the key takeaways from the Migraine Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Migraine treatment therapies with a considerable amount of success over the years. 
  • Migraine companies working in the treatment market are Pulmatrix, Vaxxinity, Inc., Tonix Pharmaceuticals, Inc., AEON Biopharma, Inc., Eli Lilly and Company, Satsuma Pharmaceuticals, Axsome Therapeutics, Pfizer, and others, are developing therapies for the Migraine treatment 
  • Emerging Migraine therapies in the different phases of clinical trials are- PUR-3100, UB-313, TNX-1900, ABP-450, LY3451838, STS-101, AXS 07, Zavegepant, and others are expected to have a significant impact on the Migraine market in the coming years.   
  • In August 2023, ReMMiD-C, the Reduction in Monthly Migraine Days-CGRP study, is the second active randomised clinical trial in migraine that Click Therapeutics, Inc. , a pioneer in Digital TherapeuticsTM as prescription medical treatments, has announced. It is a fully remote and decentralised trial that aims to determine the effectiveness and safety of digital therapeutics in reducing the number of monthly migraine days for adults with episodic migraine who are currently receiving Ca Additionally, in March, Click began the ReMMi-D study (NCT05853900), a phase 3 pivotal registration study with about 558 patients
  • In August 2023, The company Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided an update on the growing body of clinical data supporting the potential therapeutic benefits of its second-generation (Gen-2) 15 milliamp (mA) neurostimulation device. This included the findings of a study in patients with migraine headaches, which showed a significant and statistically significant benefit in patients
  • In September 2022, Axsome Therapeutics, Inc. stated that it plans to resubmit its New Drug Application (NDA) for AXS-07 for the acute treatment of migraine in the third quarter of 2023 following a Type A meeting with the U.S. Food and Drug Administration (FDA).
  • In August 2022, An open-label, multiple-dose evaluation of the effectiveness and safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor was started by Axsome Therapeutics, Inc.


Migraine Overview

A neurologic condition called migraine frequently results in a severe headache. The headache occurs in bursts, and occasionally it’s accompanied by nausea, vomiting, and light sensitivity. The most common cause of impairment in the world is migraine. About 15% of Americans suffer from migraines.


Get a Free Sample PDF Report to know more about Migraine Pipeline Therapeutic Assessment-



Emerging Migraine Drugs Under Different Phases of Clinical Development Include:

  • PUR-3100: Pulmatrix
  • UB-313: Vaxxinity, Inc.
  • TNX-1900: Tonix Pharmaceuticals, Inc.
  • ABP-450: AEON Biopharma, Inc.
  • LY3451838: Eli Lilly and Company
  • STS-101: Satsuma Pharmaceuticals
  • AXS 07: Axsome Therapeutics
  • Zavegepant: Pfizer
  • AXS-07: Axsome Therapeutics
  • Zavegepant: Biohaven Pharmaceuticals


Migraine Route of Administration

Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal


Migraine Molecule Type

Migraine Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule


Migraine Pipeline Therapeutics Assessment

  • Migraine Assessment by Product Type
  • Migraine By Stage and Product Type
  • Migraine Assessment by Route of Administration
  • Migraine By Stage and Route of Administration
  • Migraine Assessment by Molecule Type
  • Migraine by Stage and Molecule Type


DelveInsight’s Migraine Report covers around 30+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Further Migraine product details are provided in the report. Download the Migraine pipeline report to learn more about the emerging Migraine therapies


Some of the key companies in the Migraine Therapeutics Market include:

Key companies developing therapies for Migraine are – Klaria Pharma Holding AB, Biohaven Pharmaceutical Holding Company Ltd, Eli Lilly and Co, H. Lundbeck AS, Ceruvia Lifesciences LLC, AbbVie Inc., and others.


Migraine Pipeline Analysis:

The Migraine pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Migraine with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment.
  • Migraine key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Migraine Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Migraine market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Migraine drugs and therapies


Migraine Pipeline Market Drivers

  • Increasing prevalence of Migraine, significant progress is being made in the preventative treatment of chronic migraine, growing awareness regarding migraine are some of the important factors that are fueling the Migraine Market.


Migraine Pipeline Market Barriers

  • However, lack of proper diagnosis, various side-effects associated with the available drugs and other factors are creating obstacles in the Migraine Market growth.


Scope of Migraine Pipeline Drug Insight    

  • Coverage: Global
  • Key Migraine Companies: Pulmatrix, Vaxxinity, Inc., Tonix Pharmaceuticals, Inc., AEON Biopharma, Inc., Eli Lilly and Company, Satsuma Pharmaceuticals, Axsome Therapeutics, Pfizer, and others
  • Key Migraine Therapies: PUR-3100, UB-313, TNX-1900, ABP-450, LY3451838, STS-101, AXS 07, Zavegepant, and others
  • Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies
  • Migraine Market Dynamics: Migraine market drivers and Migraine market barriers 


Request for Sample PDF Report for Migraine Pipeline Assessment and clinical trials


Table of Contents 

1. Migraine Report Introduction

2. Migraine Executive Summary

3. Migraine Overview

4. Migraine- Analytical Perspective In-depth Commercial Assessment

5. Migraine Pipeline Therapeutics

6. Migraine Late Stage Products (Phase II/III)

7. Migraine Mid Stage Products (Phase II)

8. Migraine Early Stage Products (Phase I)

9. Migraine Preclinical Stage Products

10. Migraine Therapeutics Assessment

11. Migraine Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Migraine Key Companies

14. Migraine Key Products

15. Migraine Unmet Needs

16 . Migraine Market Drivers and Barriers

17. Migraine Future Perspectives and Conclusion

18. Migraine Analyst Views

19. Appendix

20. About DelveInsight


About DelveInsight


DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services